Review
Version 1
Preserved in Portico This version is not peer-reviewed
Inflammatory Bowel Disease Therapies and Acute Liver Injury
Version 1
: Received: 18 April 2024 / Approved: 19 April 2024 / Online: 19 April 2024 (08:05:31 CEST)
How to cite: Catanzaro, R.; Marotta, F.; Yazdani, A.; Sciuto, M. Inflammatory Bowel Disease Therapies and Acute Liver Injury. Preprints 2024, 2024041317. https://doi.org/10.20944/preprints202404.1317.v1 Catanzaro, R.; Marotta, F.; Yazdani, A.; Sciuto, M. Inflammatory Bowel Disease Therapies and Acute Liver Injury. Preprints 2024, 2024041317. https://doi.org/10.20944/preprints202404.1317.v1
Abstract
Drug-induced liver disease represents one of the main problems in the therapeutic field. As with most pathologies, also in this case various risk factors can be recognised, such as age, sex, but also the gut microbiota. Therefore all drugs on the market can, in fact, cause hepatotoxicity of varying degrees. Drugs used in the treatment of IBD can also cause these adverse effects and even lead to DILI. In this review, the various classes of drugs used in the treatment of IBD were taken into consideration and the various adverse effects on the liver were illustrated. In particular, a major role has emerged regarding hepatotoxicity of immunosuppressants. Biological drugs, however, seem to be responsible for these complications to a much lesser extent.
Keywords
Drug-induced liver injury; cholestasis; hepatotoxicity; liver failure.
Subject
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment